Hemoglobin-based
oxygen carriers were developed as an alternative for
blood transfusion. However, the research progress for their further clinic applications was slow in recent several years.
Hypoxia is found in most solid
tumors, which is responsible for the
tumor formation, increased
metastasis, drug resistance during therapeutic process as well as poor patient survival. In this work, novel
hemoglobin (Hb) loaded nanoliposomes, as artificial red cells for
oxygen delivery, were optimized by screening various types of
phospholipids and analyzing different mole ratio of
phospholipid to
cholesterol. The nanoliposomes presented a high encapsulating efficiency to
hemoglobin and also significantly enhanced its stability. The obtained
hemoglobin loaded nanoliposome (HLL) could be lyophilized for long term storage. HLL did not cause significant cell death in the concentration range of 0-100μg equivalent
Hb/mL under normoxia and
hypoxia incubation conditions, suggesting the low cytotoxicity and high biocompatibility of HLL. Importantly, HLL could efficiently accumulate into subcutaneous and deep orthotopic
tumors, inducing a significant decrease of
hypoxia-inducible factors 1α subunits (HIF-1α) in the
tumors and remarkably reduced expression of
vascular endothelial growth factor (
VEGF). The study of acute and chronic toxicity indicated that HLL did not induce obvious damage to main organs of mice after
intravenous injections with total Hb dose of 120mg/kg. We presented a promising method for relieving the
hypoxia degree in solid
tumors and down-regulating HIF-1α
protein by directly delivering
oxygen into
tumors, which will be very helpful for subsequent
cancer therapy.